Sales & Earnings In Brief
This article was originally published in The Tan Sheet
Executive Summary
GSK core OTCs outpace market growth; Sanofi consumer business surges in emerging markets; broad drivers fuel GNC growth; USANA builds bonds in China; bullish Mead Johnson raises outlook; more Sales & Earnings In Brief.
You may also be interested in...
Only Alli Remains After Glaxo’s OTC Transaction With Aspen
GlaxoSmithKline sells 19 OTC brands – worth about 1% of its consumer healthcare business – outside the U.S., Canada and Europe to South African firm Aspen Pharmacare. Weight-loss drug alli is GSK’s final remaining non-core OTC following the $263 million deal.
In Brief
Prestige Brands growth argues against Genomma bid; Abbott Nutrition refutes China research report; FDA expects annual doubling of supplement AERs; FTC settles with acai online marketers; Schiff Nutrition revises full-year sales growth guidance upward; more news In Brief.
Nu Skin Adds Galvanic Body Device, R2 Supplement To ageLOC Line
Building on its profitable ageLOC portfolio, which has generated $700 million in sales in the short three-year span the products have been on the market, Nu Skin Enterprise, Inc. launches two new products this month. The ageLOC Galvanic Body Spa skin-treatment system (with accompanying body-shaping gel and body-contouring lotion) will bow in the U.S., Europe and South Pacific markets, while the ageLOC R2 supplement system is rolling out in Japan and Korea.